Country: United States
Language: English
Source: NLM (National Library of Medicine)
EMTRICITABINE (UNII: G70B4ETF4S) (EMTRICITABINE - UNII:G70B4ETF4S), TENOFOVIR DISOPROXIL FUMARATE (UNII: OTT9J7900I) (TENOFOVIR ANHYDROUS - UNII:W4HFE001U5)
Teva Pharmaceuticals USA, Inc.
ORAL
PRESCRIPTION DRUG
Emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg [see Clinical Studies (14)] . Emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP [see Dosage and Administration (2.2), Warnings and Precautions (5.2)]. Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP is contraindicated in individuals with unknown or positive HIV-1 status [see Warnings and Precautions (5.2)] . Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to emtricitabine and tenofovir disoproxil
Emtricitabine and tenofovir disoproxil fumarate tablets are available as follows: 200 mg of emtricitabine and 300 mg of tenofovir DF (equivalent to 245 mg of tenofovir disoproxil) - white to off-white, film-coated, modified capsule-shaped tablets, debossed with "TV" on one side of the tablet and with "C75" on the other side. Available in unit of use bottles of 30 (containing a desiccant [silica gel canister] and closed with a child-resistant closure), NDC 0093-7704-56. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
FUMARATE TABLET, FILM COATED Teva Pharmaceuticals USA, Inc. ---------- MEDICATION GUIDE Emtricitabine and Tenofovir Disoproxil Fumarate (em" trye sye′ ta been and ten of′ oh vir dye" soe prox′ il fue′ ma rate) Tablets Read this Medication Guide before you start taking emtricitabine and tenofovir disoproxil fumarate tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. This Medication Guide provides information about two different ways that emtricitabine and tenofovir disoproxil fumarate tablets may be used. See the section “What are emtricitabine and tenofovir disoproxil fumarate tablets?” for detailed information about how emtricitabine and tenofovir disoproxil fumarate tablets may be used. What is the most important information I should know about emtricitabine and tenofovir disoproxil fumarate tablets? Emtricitabine and tenofovir disoproxil fumarate tablets can cause serious side effects, including: • Worsening of hepatitis B virus infection (HBV). Your healthcare provider will test you for HBV before start or when you start treatment with emtricitabine and tenofovir disoproxil fumarate tablets. If you have HBV infection and take emtricitabine and tenofovir disoproxil fumarate tablets, your HBV may get worse (flare-up) if you stop taking emtricitabine and tenofovir disoproxil fumarate tablets. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. • Do not run out of emtricitabine and tenofovir disoproxil fumarate tablets. Refill your prescription or talk to your healthcare provider before your emtricitabine and tenofovir disoproxil fumarate tablets is all gone. • Do not stop taking emtricitabine and tenofovir disoproxil fumarate tablets without first talking to your healthcare provider. • If you stop taking emtricitabine and tenofovir disoproxil fumarate tablets, your healthcare provider will need to check your hea Read the complete document
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE- EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLET, FILM COATED TEVA PHARMACEUTICALS USA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2004 WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B AND RISK OF DRUG RESISTANCE WITH USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PREP) IN UNDIAGNOSED EARLY HIV-1 INFECTION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ SEVERE ACUTE EXACERBATIONS OF HEPATITIS B (HBV) HAVE BEEN REPORTED IN HBV-INFECTED INDIVIDUALS WHO HAVE DISCONTINUED EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. HEPATIC FUNCTION SHOULD BE MONITORED CLOSELY IN THESE INDIVIDUALS WHO DISCONTINUE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. IF APPROPRIATE, ANTI-HEPATITIS B THERAPY MAY BE WARRANTED. (5.1) EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS USED FOR HIV-1 PREP MUST ONLY BE PRESCRIBED TO INDIVIDUALS CONFIRMED TO BE HIV-NEGATIVE IMMEDIATELY PRIOR TO INITIATING AND AT LEAST EVERY 3 MONTHS DURING USE. DRUG-RESISTANT HIV-1 VARIANTS HAVE BEEN IDENTIFIED WITH THE USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PREP FOLLOWING UNDETECTED ACUTE HIV-1 INFECTION. DO NOT INITIATE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PREP IF SIGNS OR SYMPTOMS OF ACUTE HIV INFECTION ARE PRESENT UNLESS NEGATIVE INFECTION STATUS IS CONFIRMED. (5.2) RECENT MAJOR CHANGES Indications and Usage HIV-1 Pre-Exposure Prophylaxis (PrEP) (1.2) 06/2020 Dosage and Administration HIV-1 Screening for Individuals Receiving emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP (2.2) 06/202 Read the complete document